NIH experts review monkeypox challenges
Lessons learned from the public health responses to the HIV and COVID-19 pandemics should help guide the response to the current outbreak of monkeypox, National Institutes of Health… read more.
Lessons learned from the public health responses to the HIV and COVID-19 pandemics should help guide the response to the current outbreak of monkeypox, National Institutes of Health… read more.
Treatment with dupilumab appears to improve survival rates for patients with moderate to severe COVID-19. Researchers reported these findings on August 16, 2022 in Open Forum of Infectious… read more.
People who supplement rescue inhalers with a second asthma medication sometimes get little relief at first, but there’s good news: Those who keep trying different options often find… read more.
UBC researchers demonstrated in 2019 that pre-schoolers can safely overcome peanut allergies with a treatment called oral immunotherapy. Now they have evidence that the earlier pre-schoolers start this… read more.
Amgen announced results from a pooled post-hoc analysis of the pivotal NAVIGATOR Phase III and PATHWAY Phase IIb trials showed Tezspire (tezepelumab-ekko) demonstrated reductions in the annualized asthma… read more.
A new protein-based antiviral nasal spray developed by researchers at Northwestern University, University of Washington and Washington University at St. Louis is being advanced toward Phase I human… read more.
A new study, led by researchers from the University of California, Irvine, identifies a reason for why older adults are significantly more susceptible to infectious diseases than younger… read more.
A small preliminary study from Northwestern Medicine has shown that a blood test may identify risk of stillbirth and placentitis in pregnant individuals who have had COVID-19. The… read more.
NICE (UK)-Palforzia from Aimmune/Nestle is recommended, within its marketing authorisation, as an option for treating peanut allergy in children aged 4 to 17. It can be continued in… read more.
Not too long ago the idea of taking, for instance a skin cell and transforming it into a muscle cell was unthinkable. About 10 years ago, however, revolutionary… read more.
The FDA approved the only biologic for severe asthma without any phenotype or biomarker limitations, manufacturers AstraZeneca and Amgen announced. The first-in-class biologic tezepelumab-ekko (Tezspire) is indicated as an… read more.
The biologic drug dupilumab lowers the rate of severe asthma attacks and improves lung function and asthma control for children ages 6 to 11, researchers reported on December 9, 2021 in… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.